Spero Therapeutics Inc (NASDAQ:SPRO) Posts Q3 Revenue and EPS Beat

Financial Performance Spero Therapeutics Inc (NASDAQ:SPRO) reported third-quarter 2025 revenue of $5.44 million, significantly surpassing analyst expectations of $0. The company's non-GAAP earnings per share came in at -$0.13, a notable improvement over the estimated -$0.255. This performance represents a substantial beat on both top and bottom-line estimates.

The company's financial results show:

• Revenue beat estimates by $5.44 million
• EPS exceeded expectations by $0.125
• Both metrics showed strong outperformance relative to projections

Market Reaction Following the earnings release, SPRO shares experienced mixed trading activity. The stock declined approximately 0.4% in after-hours trading, contrasting with recent positive momentum. Over the past month, shares had gained about 3.8%, with two-week and one-week performances showing gains of 3.4% and 2.1% respectively. This divergence between the earnings beat and immediate price reaction suggests investors may be weighing other factors beyond the quarterly results.

Business Update Highlights The earnings release included several important business developments. Management highlighted the presentation of Phase 3 PIVOT-PO trial results for tebipenem HBr in complicated urinary tract infections at IDWeek in October. The company continues to advance its pipeline, which includes multiple investigational treatments targeting multi-drug resistant bacterial infections and rare diseases. These clinical programs represent the core value drivers for the clinical-stage biopharmaceutical company.

Forward Outlook and Analyst Expectations Looking ahead, analysts project full-year 2025 sales of approximately $20.5 million, with an estimated EPS of -$0.85. For the fourth quarter of 2025, expectations include:

• Revenue estimate: $0
• EPS estimate: -$0.22

The company's ability to maintain its clinical development momentum while managing expenses will be crucial in meeting or exceeding these future projections. The lack of specific forward guidance in the press release regarding Q4 or full-year 2025 performance leaves investors relying on current analyst estimates for benchmarking future results.

For detailed earnings information and updated analyst estimates, visit the SPRO earnings page.

Disclaimer: This article provides financial analysis for informational purposes only and does not constitute investment advice. Readers should conduct their own research and consult with financial advisors before making investment decisions.